骨髓增生异常综合征的研究进展

高锦程; 洪珞珈

doi:10.13201/j.issn.1004-2806.2018.01.017

骨髓增生异常综合征的研究进展

高锦程,
洪珞珈^,

- 哈尔滨医科大学附属第四医院血液科(哈尔滨, 150001)

详细信息

通讯作者: 洪珞珈,E-mail:hongluojia@sina.com

中图分类号: R733.7

收稿日期: 2017-03-03

The research progress of myelodysplastic syndrome

GAO Jincheng,
HONG Luojia^,

More Information

Corresponding author: HONG Luojia, E-mail: hongluojia@sina.com

Received Date: 03 March 2017

摘要

- 骨髓增生异常综合征 /
- 发病机制 /
- 诊断分型 /
- 风险评估
Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal disorders of bone marrow characterized by peripheral blood cytopenia and can progress to leukeamia.The clinical course of patients with MDS is characterized by wide variability reflecting the underlying genetic and biological heterogeneity of the disease.Diagnosis is currently based on the presence of peripheral blood cytopenias,peripheral blood and bone marrow dysplasia/blasts,and clonal cytogenetic abnormalities.Incomplete understanding of disease pathogenesis,the inherent biological complexity of MDS and the presence of poor performance status in the typical older patients with MDS,have been major impediments to development of effective novel therapies.In this review,we will discuss recent advances in our collective understanding of the pathogenesis,diagnosis classification and risk assessment of MDS.
- melodysplastic syndrome /
- pathogenesis /
- diagnosis classification /
- risk assessment

HTML全文

参考文献(34)

[1]	Haferlach T, Nagata Y, Grossmann V, et al.Landscape of genetic lesions in 944patients with myelodysplastic syndromes[J].Leukemia, 2014, 28:241-247.
[2]	Ganguly BB, Dolai TK, De R, et al.Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome (MDS) and a brief review[J].J Cancer Res Ther, 2016, 12:1203-1206.
[3]	McQuilten ZK, Sundararajan V, Andrianopoulos N, et al.Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes[J].Cancer, 2015, 121:2892-2899.
[4]	Lee EJ, Podoltsev N, Gore SD, et al.The evolving field of prognostication and risk stratification in MDS:Recent developments and future directions[J].Blood Rev, 2016, 30:1-10.
[5]	Gill H, Leung AY, Kwong YL.Molecular and cellular mechanisms of myelodysplastic syndrome:Implications on targeted therapy[J].Int J Mol Sci, 2016, 17:440.
[6]	Bejar R, Stevenson KE, Caughey B, et al.Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem cell transplantation[J].Clin Oncol, 2014, 32:2691-2698.
[7]	Wang J, Ai X, Gale RP, et al.TET2, ASXL1 and EZH2mutations in Chinese with myelodysplastic syndromes[J].Leuk Res, 2013, 37:305-311.
[8]	Zhang L, Padron E, Lancet J.The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes[J].Leuk Res, 2015, 39:6-17.
[9]	Nebbioso A, Benedetti R, Conte M, et al.Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia[J].Expert Opin Ther Targets, 2015, 19:1187-1202.
[10]	Traina F, Visconte V, Elson P, et al.Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J].Leukemia, 2014, 28:78-87.
[11]	Lin CC, Hou HA, Chou WC, et al.IDH mutations are closely associated with mutations of DNMT3A, ASXL1and SRSF2in patients with myelodysplastic syndromes and are stable during disease evolution[J].Am J Hematol, 2014, 89:137-144.
[12]	Thol F, Friesen I, Damm F, et al.Prognostic significance of ASXL1mutations in patients with myelodysplastic syndromes[J].J Clin Oncol, 2011, 29:2499-2506.
[13]	Inoue D, Kitaura J, Togami K, et al.Myelodysplastic syndromes are induced by histone methylation-altering ASXL1mutations[J].J Clin Invest, 2013, 123:4627-4640.
[14]	Pellagatti A, Boultwood J.Splicing factor gene mutations in the myelodysplastic syndromes:impact on disease phenotype and therapeutic applications[J].Adv Biol Regul, 2017, 63:59-70.
[15]	Itzykson O, Kosmider A, Renneville, et al.Prognostic score including gene mutations in chronic myelomonocytic leukemia[J].J Clin Oncol, 2013, 31:2428-2436.
[16]	Harada H, Harada Y.Recent advances in myelodysplastic syndromes:molecular pathogenesis and its implications for targeted therapies[J].Cancer Sci, 2015, 106:329-336.
[17]	Kurtovic KA, Przychodzen B, Singh J, et al.PRPF8defects cause missplicing in myeloid malignancies[J].Leukemia, 2015, 29:126-136.
[18]	Stengel A, Kern W, Haferlach T, et al.The impact of TP53mutations and TP53deletions on survival varies between AML, ALL, MDS and CLL:an analysis of3 307cases[J].Leukemia, 2016, 31:705-711.
[19]	Wong TN, Ramsingh G, Young AL, et al.Role of TP53mutations in the origin and evolution of therapyrelated acute myeloid leukaemia[J].Nature, 2015, 518:552-555.
[20]	Saft L, Karimi M, Ghaderi M, et al.P53protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del (5q)[J].Haematologica, 2014, 99:1041-1049.
[21]	Damm F, Chesnais V, Nagata Y, et al.BCOR and BCORL1mutations in myelodysplastic syndromes and related disorders[J].Blood, 2013, 122:3169-3177.
[22]	Pellagatti A, Boultwood J.The molecular pathogenesis of the myelodysplastic syndromes[J].Eur J Haematol, 2015, 95:3-15.
[23]	Daw S, Chatterjee R, Law A, et al.Analysis of hematopathology and alteration of JAK1/STAT3/STAT5signaling axis in experimental myelodysplastic syndrome[J].Chem Biol Interac, 2016, 260:176-185.
[24]	Leung AY, Man CH, Kwong YL.FLT3inhibition:Amoving and evolving target in acute myeloid leukaemia[J].Leukemia, 2013, 27:260-268.
[25]	Badar T, Patel KP, Thompson PA, et al.Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes[J].Leuk Res, 2015, 39:1367-1374.
[26]	Thota S, Viny AD, Makishima H, et al.Genetic alterations of the cohesin complex genes in myeloid malignancies[J].Blood, 2014, 124:1790-1798.
[27]	Sundaramoorthy S, Vázquez-Novelle MD, Lekomtsev S, et al.Functional genomics identifies a requirement of pre-mRNA splicing factors for sister chromatid cohesion[J].EMBO J, 2014, 33:2623-2642.
[28]	Thol F, Bollin R, Gehlhaar M, et al.Mutations in the cohesion complex in acute myeloid leukemia:clinical and prognostic implications[J].Blood, 2014, 123:914-920.
[29]	Papaemmanuil E, Gerstung M, Malcovati L, et al.Clinical and biological implications of driver mutations in myelodysplastic syndromes[J].Blood, 2013, 122:3616-3627.
[30]	Lukackova R, Bujalkova MG, Majerova L, et al.Molecular genetic methods in the diagnosis of myelodysplastic syndromes:a review[J].Palacky Olomouc Repub, 2014, 158:339-345.
[31]	Shastri A, Will B, Steidl U, et al.Stem and progenitor cell alterations in myelodysplastic syndromes[J].Blood, 2017, 129:1586-1594.
[32]	Arber DA, Orazi A, Hasserjian R, et al.The 2016revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood, 2016, 127:2391-2405.
[33]	肖志坚.骨髓增生异常综合征的精准诊断与治疗:现况与问题[J].临床血液学杂志, 2017, 30 (5):339-341.
[34]	Nomdedeu M, Calvo X, Pereira A, et al.Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients.A study by the spanish group of myelodysplastic syndromes[J].Genes Chromosomes Cancer, 2016, 55:322-327.